InveniAI® has introduced ChatAlphaMeld™, a tool designed to provide expert answers and insights for drug and target discovery.
The ChatAlphaMeld interface harnesses GPT-4 and AlphaMeld’s extensive proprietary knowledgebase, which encompasses 1,968,753,898 edges (or associations) between 649,893,375 nodes (or entities), and includes more than 49,000 drugs, 20,000 genes, 30,000 disease/symptoms, 73,000 expression datasets, 1,400 cell types, 483,000 clinical events, and over a billion scientific literature sentences to triangulate disease-target-drug associations.
For a limited time, ChatAlphaMeld is available to users who sign up at https://alphameld.com/web/